Scientific Advisory Board
Expert Insight Driving Innovation in Clinical Research
The TFS Scientific Advisory Board (SAB) plays a critical role in guiding the strategy, scientific rigor, and innovation behind our global clinical research.
Meet Our Scientific Advisors
Comprised of world-renowned experts across key therapeutic areas, our SAB members bring decades of experience spanning academia, clinical practice, and drug development. Their deep understanding of disease biology, trial design, and regulatory strategy ensures that every study we support is built on a foundation of both scientific excellence and patient-centered impact. Whether advising on complex neurological programs, emerging inflammatory targets, or rare disease studies, our advisors work closely with TFS leadership to shape smarter, faster solutions for biopharma sponsors around the world.
Dr. Lynne Hughes, BMedSci, PhD, PMP
Expert in Neurodegenerative and Neuro-Orphan Diseases
Dr. Hughes is a neuroscience leader with over 35 years in global clinical development, currently serving as Chief People Officer at the Global Alzheimer’s Platform Foundation. Formerly VP and Global Head of Medical Strategy, Neurology at IQVIA, she brings deep expertise in Alzheimer’s, Parkinson’s, and neurocognitive trials, shaping programs through strategic and operational insight.
Dr. Rob Rubens, MD, MBA, FAAN
Expert in Clinical Neuroscience and Neurotherapeutic Development
Dr. Rubens is a board-certified neurologist with 40+ years of combined clinical and industry experience. A lead architect of several Parkinson’s drug programs, including the FDA-approved CREXONT , he advises on full-spectrum CNS trial strategy from Phase I to NDA.
Dr. Orest Hurko, MD
Expert in Neurogenetics and Translational Medicine
Dr. Hurko is a board-certified neurologist and geneticist with more than 40 years of experience spanning clinical care, neuroscience research, and biopharma leadership. He has led global translational medicine programs for neurology and rare genetic diseases and contributed to the development of multiple approved therapies, including those for Parkinson’s, neonatal seizures, and multiple sclerosis.
Dr. Jonathan Krant, MD, MPH, FACP
Expert in Immunology, Rheumatology, and Inflammatory Disease
Dr. Krant is a board-certified expert in internal medicine and rheumatology, with 30+ years bridging patient care, advocacy, and clinical development. He has led international research programs and regulatory responses and has authored more than 20 publications in autoimmune and inflammatory disease.
Dr. Luca Bartolini, MD, FAAN, FAES
Expert in Child Neurology, Epilepsy and Neurocritical Care
Dr. Bartolini is a board-certified neurologist and pediatrician with expertise in child neurology and epilepsy. An internationally recognized leader in pediatric epilepsy, he has directed Brown University’s multidisciplinary Pediatric Epilepsy Program and authored more than 50 peer-reviewed publications across neurology, epilepsy, and neurocritical care. He has also advanced diagnostic methods for neurotropic viruses in children with seizures and is one of few European physicians elected Fellow of both the American Academy of Neurology and the American Epilepsy Society.